Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > INCY Incyte > Detailed Quotes

INCY Incyte

Watchlist
68.830
+2.190+3.29%
Close 10/03 16:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
69.070
Open
67.130
Turnover
93.39M
Low
66.500
Pre Close
66.640
Volume
1.37M
Market Cap
15.31B
P/E(TTM)
16.20
52wk High
84.860
Shares
222.43M
P/E(Static)
16.12
52wk Low
61.910
Float Cap
12.64B
Bid/Ask %
0.00%
Historical High
153.150
Shs Float
183.64M
Volume Ratio
0.92
Historical Low
1.850
Dividend TTM
--
Div Yield TTM
--
P/B
3.75
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.74%
Amplitude
3.86%
Avg Price
68.401
Lot Size
1
Float Cap
12.64B
Bid/Ask %
0.00%
Historical High
153.150
Shs Float
183.64M
Volume Ratio
0.92
Historical Low
1.850
Dividend TTM
--
P/B
3.75
Dividend LFY
--
Turnover Ratio
0.74%
Amplitude
3.86%
Avg Price
68.401
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
CEO: Hoppenot, Herve
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top